Orphan Drugs & Rare Diseases Global Congress 2018 Europe
About This Event
Find the conference:
http://www.orphandrugscongress.com
This year’s congress will look into Practical strategies and best practices on challenges, innovations, technologies and concepts surrounding orphan drugs and rare diseases.
There are more than 7,000 rare diseases identified, however, only a fraction of them have approve treatment available. “Orphan drugs” are intended to treat diseases so rare that sponsors are reluctant to develop them under usual marketing conditions. Currently, the regulatory climate is favourable with both FDA and European Medicines Agency, as they offer incentives, tax credits, user waivers and marketing exclusivity. As a result, the number of therapies approved for rare diseases for the past two decades has grown exponentially.
The 3-day Congress will provide a unique platform for the convergence of stakeholders in the orphan drugs industry to discuss and network with top tier government, hospitals, pharmaceuticals, biopharmaceuticals, non-profit organisations, orphan drugs developers as well as regional and local manufacturers. We are putting together an agenda that address the driving macroeconomic factors, policies and issues that will steer the development of orphan drugs globally including commercialisation, policies, reimbursement, pricing and more.
The Congress will also provide an interactive, cutting edge and comprehensive discussion and networking format led by key industry experts with intimate knowledge in the industry. Gain the practical strategies and best practices on challenges, innovations, technologies and concepts surrounding orphan drugs and rare diseases.